News

Causeway Therapeutics

Longevity investment bulletin: Five Alarm Bio, Capsida, MyMD and more

Investment Investment

Causeway Therapeutics secures £8.75 million for Phase 2 trial of tendinopathy therapy

Investment Investment

Find us here ...

Subscribe to our newsletter

First Longevity Ltd is an appointed representative of Prospect Capital Ltd which is authorised and regulated by the Financial Conduct Authority.
The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding and knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

No spam - just the good stuff

More